All In Biotech

Free tool

FAERS Monitor: Nesina

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022271 or its brand name (Nesina, Alogliptin Benzoate). Reports on generic versions are filed under their own applications.

Reports

3,416

Serious

2,992

88% of reports

Hospitalization

1,571

Death reported

356

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea133
  • nausea123
  • vomiting110
  • pemphigoid102
  • acute kidney injury101
  • rash97
  • malaise93
  • dyspnoea86
  • blood glucose increased84
  • pneumonia84
  • decreased appetite80
  • pruritus78
  • pyrexia78
  • dizziness77
  • drug ineffective76

Reports by year received

View as table
YearReports
201112
201275
2013202
2014272
2015286
2016272
2017275
2018339
2019343
2020287
2021259
2022186
2023214
2024238
2025129
202627

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,743 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
pemphigoidSignal10284.369.68,208
acute kidney injurySignal1014.13.4232
blood glucose increasedSignal842.72.292
decreased appetiteSignal802.11.747
pneumonia841.61.318
vomiting1101.41.215
pyrexia781.41.18
rash971.41.110
malaise931.31.16
diarrhoea1331.31.18
pruritus781.21.04
nausea1231.00.80
dizziness771.00.80
dyspnoea860.90.80
drug ineffective760.40.394

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.